Carcinoma of the anal canal

David T. Marshall, Charles R. Thomas

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that may significantly decrease the incidence of this cancer.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalOncology Reviews
Volume3
Issue number1
DOIs
StatePublished - Feb 25 2009

Keywords

  • Anal canal cancer
  • Chemoradiation
  • HPV
  • Organ preservation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Carcinoma of the anal canal'. Together they form a unique fingerprint.

  • Cite this